Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs offers a large range of premium, recombinant anti-IL23 antibodies, designed for best performance in demanding research uses. By using cutting-edge engineering methods, these antibodies show remarkable specificity, strong stability, and great efficacy, guaranteeing consistent and repeatable findings for important in vitro and in vivo studies.
Crucially a member of the IL-12 cytokine family, Interleukin-23 (IL-23) controls a variety of immune-mediated inflammatory disorders (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease. Like a rheostatic control or master switch, IL-23 is a vital regulating cytokine that drives and sustains a strong proinflammatory milieu and helps to alter immune cell behavior, therefore controlling the beginning and continuation of these IMIDs. This essential function emphasizes IL-23's great potential as a therapeutic target to solve the fundamental inflammatory processes in these diseases.
Interleukin-23; IL-23; P19; SGRF; IL-23A; IL23P19
It is a heterodimeric cytokine composed of an IL12B (IL-12p40) subunit (that is shared with IL12) and the IL23A (IL-23p19) subunit.
Creative Biolabs provides a range of recombinant anti-IL23 antibodies that have been meticulously crafted to ensure exceptional specificity and binding strength. From basic immunological and cancer biology studies to the creation of new therapeutic approaches, these flexible antibodies, available in several forms, cater to a wide spectrum of uses. Using a strong platform, Creative Biolabs offers cutting-edge technologies to enable researchers to push the envelope of knowledge and hasten the development of novel treatments.
Table 1. Featured anti-IL23 recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
TAB-008ML | Anti-Human IL23A Recombinant Antibody (Brazikumab) | Human | Human IgG2, λ | ELISA, IHC, FC, IP, IF, Inhib, PK |
TAB-620LC | Anti-human IL23A Recombinant Antibody | Human | Humanized antibody | ELISA |
TAB-420CL | Anti-Human IL23A Recombinant Antibody | Human | Human | FuncS |
TAB-875 | Anti-Human IL23 Recombinant Antibody (Tildrakizumab) | Human | Mouse IgG1 - kappa | Neut, ELISA, IF, IP, FuncS, FC, ICC |
HPAB-0275LY | Human Anti-IL23 Recombinant Antibody (HPAB-0275LY) | Human | Humanized IgG1 | Inhib, ELISA |
Creative Biolabs provides a wide range of strictly quality-regulated anti-IL23 recombinant antibodies. Every antibody is exactly made to target IL23 with great accuracy, and extensive testing and validation ensures remarkable specificity, strong binding affinity, and best performance for many different research uses.
Fig.1 WB analysis of anti-IL23 antibody
(Cat# TAB-620LC, Creative Biolabs).
Fig.2 DB analysis of anti-IL23 antibody
(Cat# TAB-620LC, Creative Biolabs).
Fig.3 ELISA analysis of anti-IL23 antibody
(Cat# TAB-620LC, Creative Biolabs).
Fig.4 HPLC analysis of anti-IL23 antibody
(Cat# TAB-620LC, Creative Biolabs).
Fig.5 WB analysis of anti-IL23 antibody
(Cat# TAB-008ML, Creative Biolabs).
Fig.6 ELISA analysis of anti-IL23 antibody
(Cat# TAB-008ML, Creative Biolabs).
Creative Biolabs leverages advanced genetic engineering techniques to ensure a reliable and continuous supply of high-quality anti-IL23 antibodies.
Featured Anti-IL23 Recombinant Antibody Production Platforms
Fig.7 Milligram-scale anti-IL23 recombinant antibody production.
Fig.8 Gram-scale anti-IL23 recombinant antibody production.
Creative Biolabs offers a comprehensive selection of premium anti-IL23 recombinant antibodies, available in multiple formats, designed to cater to the diverse needs of researchers worldwide.
Fig.9 Full-length anti-IL23 recombinant antibody production and modalities.
Table 2. Public drug targeting IL23.
Company | Research phase | Classification | Condition |
Alvotech (Originator) Fuji Pharma JAMP Pharma STADA Teva |
Launched - 2024 |
Follow-on Products Human Monoclonal Antibodies |
Arthritis, psoriatic Crohn's disease Inflammatory disorders Plaque psoriasis Psoriasis |
Amgen (Originator) | Launched - 2024 |
Biosimilars Follow-on Products Human Monoclonal Antibodies |
Arthritis, psoriatic Crohn's disease Inflammatory disorders Juvenile arthritis, psoriatic Plaque psoriasis Ulcerative colitis |
Almirall China Medical System (CMS) Garvan Institute Merck & Co (Originator) Merck & Co. (Merck & Co) Sun Pharma |
Launched - 2018 |
Cancer Immunotherapy Humanized Monoclonal Antibodies |
Arthritis, psoriatic Osteosarcoma Plaque psoriasis Psoriasis Vitiligo |
Centocor Ortho Biotech (Janssen) Janssen Janssen Biotech (Janssen) Janssen-Cilag (Janssen) Janssen Pharmaceutical (JP) Janssen Research & Development (Janssen) MorphoSys (Originator) Taiho |
Launched - 2017 |
Cancer Immunotherapy Human Monoclonal Antibodies |
Arthritis, psoriatic Celiac disease Crohn's disease Giant cell arteritis Hidradenitis suppurativa Juvenile arthritis, psoriatic Plaque psoriasis Polyp, adenomatous Psoriasis Pustular psoriasis (generalized) Pustular psoriasis (palmoplantar pustulosis) Rheumatoid arthritis Ulcerative colitis |
Bristol-Myers Squibb (Originator) Centocor (Janssen) Centocor Ortho Biotech (Janssen) Charité Universitätsmedizin Berlin (Charite Universitaetsmedizin Berlin) Janssen Janssen Biotech (Janssen) Janssen-Cilag (Janssen) Janssen-Ortho (Janssen) Janssen Pharmaceutical (JP) Janssen Pharmaceuticals (Janssen) Janssen Research & Development (Janssen) Johnson & Johnson Massachusetts General Hospital Mitsubishi Tanabe Pharma National Eye Institute (NEI) National Institute Allergy Infect Dis Rockefeller University |
Launched - 2008 | Human Monoclonal Antibodies |
Arthritis, psoriatic Atopic dermatitis Axial spondyloarthritis, radiographic (Ankylosing spondylitis) Crohn's disease Dermatomyositis Diabetes type 1 Giant cell arteritis Hidradenitis suppurativa Leukocyte adhesion deficiency type 1 Multiple sclerosis Pityriasis rubra pilaris Plaque psoriasis Polymyositis Pouchitis Primary biliary cholangitis Psoriasis Rheumatoid arthritis Sarcoidosis Spondyloarthritis Systemic lupus erythematosus Ulcerative colitis Uveitis |
Samsung Bioepis (Originator) Sandoz |
Registered - 2024 |
Follow-on Products Human Monoclonal Antibodies |
Arthritis, psoriatic Autoimmune disease Crohn's disease Plaque psoriasis Ulcerative colitis |
Bioeq Formycon (Originator) Fresenius Kabi |
Pre-Registered |
Follow-on Products Human Monoclonal Antibodies |
Immune-mediated inflammatory disease Immunological Disorders Inflammatory disorders Plaque psoriasis |
Dong-A ST (Originator) Intas Pharmaceuticals Meiji Seika Pharma STgen Bio |
Pre-Registered |
Follow-on Products Human Monoclonal Antibodies |
Immune-mediated inflammatory disease Inflammatory disorders Plaque psoriasis |
Qyuns Therapeutics (Originator) | Phase III |
Follow-on Products Human Monoclonal Antibodies |
Plaque psoriasis |
Biomm Bio-Thera Solutions (Originator) Hikma Pharmapark |
Phase III |
Follow-on Products Human Monoclonal Antibodies |
Psoriasis |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
For detailed information or to discuss your specific anti-IL23 recombinant antibody needs, our team is readily available to assist you. Please reach out to us at your convenience.